636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Benjamin Y. Kong(Prince of Wales Hospital), David Goldstein(New South Wales Department of Health), Rosemary Harrup(University of Tasmania), Dawn Thomas(Garvan Institute of Medical Research), T. Meniawy(Linear Clinical Research), Frank Lin(The University of Sydney), Subotheni Thavaneswaran(The University of Sydney), Katharine Cuff(Eastern Health), S. Selva‐Nayagam(Royal Adelaide Hospital), Chee Khoon Lee(The University of Sydney), Jayesh Desai(Peter MacCallum Cancer Centre), Mandy L. Ballinger(Garvan Institute of Medical Research), D. Espinoza(The University of Sydney), Michail Charakidis(Royal Adelaide Hospital), Sarah Chinchen(The University of Sydney), John Simes(The University of Sydney), Lucille Sebastian(Heidelberg University)
Cited by 0
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k